# CapsoVision, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CapsoVision, Inc). ## Overview CapsoVision, Inc. develops and commercializes capsule endoscopy solutions for gastrointestinal diagnosis, centered on its CapsoCam line of ingestible imaging capsules. The company combines disposable capsule hardware with software and cloud-based viewing workflows, including CapsoView and CapsoCloud, to help clinicians capture and review GI-tract videos. Its revenue comes from product sales, reading services, and software-as-a-service delivery options, with sales tied primarily to the number of capsules sold. CapsoVision is still in an investment phase, funding product development, regulatory work, and commercial expansion while continuing to report operating losses. ## Products & services • CapsoCam capsule endoscopy devices • CapsoCam Plus GI-tract solution • CapsoCam Colon capsule endoscopy solution • CapsoView local video viewing software • CapsoCloud cloud-based video delivery service • Video reading and interpretation services - **Capsule endoscopy hardware** (65%) — Ingestible imaging capsules sold for GI-tract diagnostic procedures. - **Cloud and software delivery** (20%) — CapsoCloud and CapsoView tools used to upload, access, and review capsule videos. - **Reading and interpretation services** (15%) — Physician or service-center review of capsule videos and generation of reports. - CapsoCam capsule endoscopy devices - CapsoCam Plus GI-tract solution - CapsoCam Colon capsule endoscopy solution - CapsoView local video viewing software - CapsoCloud cloud-based video delivery service - Video reading and interpretation services ## Customers CapsoVision sells primarily to medical practices, clinics, hospitals, and physician groups that use capsule endoscopy to evaluate gastrointestinal conditions. A portion of its revenue is routed through group purchasing organizations, which act as procurement agents for underlying healthcare members. The company also serves U.S. government-related healthcare customers, including Department of Defense and Veterans Administration-associated hospitals, which require additional IT security controls for cloud delivery. International customers matter as well because CapsoCloud must be adapted to local privacy and security rules in different countries. - **Hospitals and health systems** (primary) — Buy CapsoCam capsules and associated viewing workflows to diagnose GI-tract conditions in clinical settings. - **Medical practices and clinics** (primary) — Purchase capsule devices and reading services for outpatient GI diagnostics and patient throughput. - **Physician groups and readers** (secondary) — Use the video interpretation service and software tools to review capsule footage and produce reports. - **GPO-affiliated healthcare members** (secondary) — Buy through group purchasing organizations that negotiate procurement for member practices and hospitals. - **Government and defense-related healthcare facilities** (emerging) — Adopt CapsoCloud and capsule workflows when the company can meet stricter IT security requirements. - Medical practices and clinics buying capsule endoscopy tools for GI diagnostics - Hospitals using CapsoCam for inpatient or outpatient GI-tract evaluation - Physician groups and readers purchasing video interpretation services - GPO-affiliated healthcare members seeking negotiated procurement channels - U.S. government-related hospitals needing higher-security cloud workflows - International healthcare customers requiring country-specific privacy compliance ## Geography CapsoVision is a U.S.-based company, but its operating footprint is international because its cloud offering must comply with country-specific privacy and security rules outside the United States. Manufacturing and assembly depend heavily on Asia, especially Taiwan and Japan, where the company sources critical components and works with assembly manufacturers. The company also highlighted exposure to U.S. trade policy changes, including tariffs, which can affect product cost and gross margin. This geographic structure makes the business sensitive to cross-border logistics, regulatory compliance, and supply chain continuity. - United States is the core commercial and reporting base - Asia, especially Taiwan and Japan, is central to component sourcing and assembly - International CapsoCloud deployments require country-specific privacy and security compliance - U.S. government-related customers require additional IT security controls - Tariffs and trade policy changes can affect imported component costs - Shipping reliability matters because capsules and components must move quickly and securely ## Strategy CapsoVision is focused on expanding adoption of its GI-tract capsule endoscopy platform across new indications, patient populations, and clinical use cases. A major priority is obtaining and maintaining regulatory clearances, including 510(k) clearance for CapsoCam Colon and AI-enabled capsule products, because commercialization depends on regulatory access. The company is also trying to scale sales through its global sales team, distributors, and marketing efforts while improving reimbursement support from Medicare and other payors. At the same time, it must strengthen supply chain resilience, secure backup suppliers for critical components, and manage the capital needs of a business that is still generating losses. - **Regulatory expansion for new products** (short-term) — Commercial growth depends on securing clearances for CapsoCam Colon and AI-enabled capsules. - **Commercial scale-up** (medium-term) — The business needs broader physician and hospital adoption to increase capsule volumes and service usage. - **Supply chain resilience** (short-term) — Single-source and Asia-based suppliers create concentration risk that can disrupt product availability. - **Funding the business** (short-term) — Ongoing losses and cash burn require access to external financing to support operations and growth. - Expand CapsoCam into new indications and patient populations - Obtain and maintain 510(k) clearances for new capsule products - Commercialize AI-enabled capsule endoscopy solutions - Improve reimbursement coverage and rates from payors - Scale global sales and distributor coverage - Strengthen supply chain resilience with backup suppliers and inventory buffers - Raise additional capital to fund development and commercialization ## Risks CapsoVision faces the classic risks of an early commercial medtech company: regulatory dependence, reimbursement uncertainty, and continued operating losses. Its capsule products require 510(k) clearances and other approvals, so delays or failures in regulatory review could directly block sales of new products. The company also depends on single-source or concentrated suppliers in Asia for critical components, making it vulnerable to shortages, tariffs, shipping disruptions, and geopolitical tension. Because CapsoCloud handles sensitive medical data across jurisdictions, privacy, security, and compliance failures could create legal exposure, delay deployments, and damage customer trust. - **Regulatory clearance delays** [high] — New products such as CapsoCam Colon and AI-enabled capsules need 510(k) clearance before broad commercialization. - **Supply chain concentration** [high] — Critical components and assembly are concentrated with suppliers in Taiwan and Japan, many of them single-source. - **Reimbursement uncertainty** [high] — Adoption depends on Medicare and other payors approving adequate reimbursement for the GI-tract solution. - **Liquidity and going-concern risk** [high] — The company continues to incur losses and expects to need additional funding to support operations. - **Data privacy and cybersecurity compliance** [medium] — CapsoCloud must meet country-specific privacy rules and enhanced security requirements for some government customers. - Regulatory delays could block or slow commercialization of CapsoCam Colon and AI-enabled products - Reimbursement risk could limit adoption if payors do not cover the procedure adequately - Single-source supply chain dependence can interrupt capsule production and deliveries - Asia-based sourcing exposes the company to tariffs, trade disputes, and natural disasters - Cloud privacy and security requirements can increase cost and delay international rollout - Ongoing losses and going-concern concerns increase financing and dilution risk - Shipping and logistics disruptions can damage product availability and customer relationships ## Accounting Revenue recognition is a key accounting issue because CapsoVision sells both products and services, with different timing depending on the offering. CapsoCam capsules and reading services are recognized at a point in time, while CapsoCloud SaaS revenue is recognized over time, typically over less than one fiscal quarter, which can shift revenue between periods. Revenue is also reduced by fees paid to group purchasing organizations, so gross reported sales can differ from net revenue recognized. On the cost side, inventory, shipping, outsourced assembly, and cloud processing costs can move materially with capsule volume, while stock-based compensation and lease commitments add judgmental expense and balance-sheet considerations. - **Revenue recognition mix** — Can shift revenue between periods depending on shipment and service delivery timing - **GPO deductions** — Reduces reported revenue and can obscure underlying gross demand - **Stock-based compensation** — Impacts reported losses and dilution analysis - **Inventory and supply chain costs** — Affects cost of revenue, margins, and working capital - **Lease commitments** — Relevant to near-term cash needs and fixed-cost structure - Point-in-time revenue for capsule sales affects shipment timing and quarterly volatility - Over-time recognition for CapsoCloud can shift revenue across reporting periods - GPO fees are deducted from revenue and reduce reported net sales - Inventory and component purchases affect working capital and cost of revenue - Stock-based compensation depends on valuation assumptions and option-pricing inputs - Lease accounting matters because the company has operating lease commitments - Going-concern and financing disclosures affect how investors assess liquidity --- *Last updated: 2026-04-28T14:25:39.418272+00:00*